Annovis Bio (NYSE:ANVS) Stock Rating Reaffirmed as “Buy” by Roth Capital

Annovis Bio (NYSE:ANVS – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at Roth Capital in a research report issued on Monday, Benzinga reports. They presently have a $3.00 price target on the stock. Roth Capital‘s price target would indicate a potential upside of 233.33% from the company’s previous close.

Other equities analysts also recently issued reports about the stock. Canaccord Genuity Group reissued a “buy” rating on shares of Annovis Bio in a research note on Tuesday, August 18th. Weiss Ratings lowered shares of Annovis Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, November 10th. Finally, Wall Street Zen raised shares of Annovis Bio from a “strong sell” rating to a “sell” rating in a research note on Saturday. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Annovis Bio presently has an average rating of “Hold” and a consensus target price of $10.00.

View Our Latest Research Report on Annovis Bio

Annovis Bio Price Performance

Shares of NYSE:ANVS opened at $0.90 on Monday. Annovis Bio has a 1 year low of $0.62 and a 1 year high of $5.50. The firm has a market capitalization of $38.72 million, a PE ratio of -0.55 and a beta of 1.36. The business’s 50 day moving average price is $1.10 and its 200-day moving average price is $1.82.

Annovis Bio (NYSE:ANVS – Get Free Report) last posted its quarterly earnings data on Friday, November 13th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.08. As a group, analysts expect that Annovis Bio will post -1.32 earnings per share for the current year.

Insider Buying and Selling

In other Annovis Bio news, Director Michael Hoffman bought 5,000,000 shares of Annovis Bio stock in a transaction on Friday, November 6th. The shares were bought at an average price of $1.00 per share, for a total transaction of $5,000,000.00. Following the completion of the transaction, the director directly owned 8,364,883 shares of the company’s stock, valued at $8,364,883. This trade represents a 148.59% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. 15.92% of the stock is owned by corporate insiders.

Institutional Trading of Annovis Bio

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Empowered Funds LLC acquired a new stake in shares of Annovis Bio during the 3rd quarter worth about $42,000. State Street Corp lifted its position in Annovis Bio by 35.5% in the third quarter. State Street Corp now owns 105,335 shares of the company’s stock valued at $134,000 after buying an additional 27,600 shares during the last quarter. Nicholson Wealth Management Group LLC acquired a new position in Annovis Bio in the third quarter valued at about $25,000. StoneX Group Inc. lifted its position in Annovis Bio by 65.9% in the third quarter. StoneX Group Inc. now owns 23,996 shares of the company’s stock valued at $30,000 after buying an additional 9,531 shares during the last quarter. Finally, Headlands Technologies LLC purchased a new position in Annovis Bio during the second quarter worth about $89,000. 15.83% of the stock is owned by institutional investors and hedge funds.

About Annovis Bio

(Get Free Report)

Annovis Bio is a clinical-stage biotechnology company based in Malvern, Pennsylvania. Founded in 2008, the company researches and develops treatments for neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease.

See Also

Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.